Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 33Recruiting 25Completed 15Terminated 6Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Specimen Handling 76Cisplatin 64Drug Therapy 63Carboplatin 63Bevacizumab 63Magnetic Resonance Spectroscopy 59Radiotherapy 57Gemcitabine 54Cyclophosphamide 54pembrolizumab 52Oxaliplatin 49Capecitabine 49toripalimab 44Paclitaxel 40tislelizumab 39Standard of Care 39fludarabine 36Injections 34Fluorouracil 34Biopsy 34venetoclax 33Blood Specimen Collection 31Immune Checkpoint Inhibitors 30anlotinib 28Nivolumab 28Surgical Procedures, Operative 27Irinotecan 27Docetaxel 27Leucovorin 26Dexamethasone 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Abiraterone Acetate × 1 year × Clear all
NCT07104110 2025-08-05

Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
50 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡